At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 68 enrolled
Drug / intervention
Dapsone Geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
In Brief
A Phase 4 clinical trial evaluating Dapsone Gel for Acne Vulgaris. Completed, enrolled 68 participants across 1 site.
Detailed Summary
This study will evaluate the effect of dapsone gel in female subjects with skin of color (Fitzpatrick Skin Types IV, V, and VI) with acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedJan 2014
Primary CompletionJun 2014
Study CompletionSep 2014
TodayJul 2026
First PostedJan 10, 2014
Enrollment StartDec 1, 2013
Primary CompletionJun 1, 2014
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.5 years ago
Interventions
Dapsone Geldrug
Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.